Specialty Pharmacy

The results of a new study show a new view of genetic regulation by uncovering how genes and disease are related.

As specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.

Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.

The FDA has also converted the indication for pembrolizumab from an accelerated to a full, regular approval for patients with urothelial carcinoma.

Experts from Emory Healthcare and Winship Cancer Institute discuss the management of oncology patients by pharmacists within an NCI-designated comprehensive cancer center.

The mutated genes in question, TET2 and DNMT3A, each influence the efficacy of treatment in different ways.

Brad McElya, PharmD, director of specialty health solutions at Walgreens, discusses the critical role pharmacists play in providing HIV prevention drugs in communities across America.

Silmitasertib has produced clinical benefit as a monotherapy and in combination with drugs such as gemcitabine and cisplatin.

Pharmacists can help patients with allergies acquire the right oral antihistamines or decongestants, steroid or decongestant nasal sprays, and/or eye drops based on symptoms.

As the price tags for therapies coming to market have soared into the hundreds of thousands and even millions on occasion, paying for them has become an ever-greater cause of concern and focus area.

Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.

The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.

Specialty pharmacists’ roles have grown in new and exciting ways in recent years, and those changes have directly impacted health outcomes for all specialty patients, including patients with HIV.

It is now the only 4-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe, the company said.

A proactive approach can ensure that the patient is getting the right therapy at the right time and the right treatment plan with the least amount of waste.

English discussed the challenges and highlights of her time in the trial, in addition to what she feels health care professionals should learn from her own treatment experience.

The pandemic taught the pharmacy to provide a deeper level of personalized care and communication than in the past.

Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.

When trying determine which drug can be called the most expensive on the market, there are 2 potential answers depending on how you define the question.

Octagam 10% is indicated for the treatment of chronic immune thrombocytopenic purpura in adults and dermatomyositis (DM) in adults

Ten quiz questions to assess your knowledge on common multiple sclerosis treatments.

Avalglucosidase alfa-ngpt is indicated for patients aged 1 year and older with late-onset Pompe disease.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.

Ten quiz questions to assess your knowledge on common rheumatoid arthritis treatments.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss how to manage the logistical challenges that arise during the administration of CAR T therapy in inpatient and outpatient settings for patients with multiple myeloma.

Workflow in the clinic and the pharmacy are critical for the implementation of a new and novel medication therapy, such as cabotegravir-rilpivirine.